메뉴 건너뛰기




Volumn 42, Issue 4, 2012, Pages 284-293

Antiviral agents against influenza viruses

Author keywords

Antiviral drugs; Combination therapy; Influenza; Neuraminidase; Resistance

Indexed keywords

ANTIVIRUS AGENT;

EID: 84922686847     PISSN: 15982467     EISSN: None     Source Type: Journal    
DOI: 10.4167/jbv.2012.42.4.284     Document Type: Review
Times cited : (11)

References (69)
  • 4
    • 80051970247 scopus 로고    scopus 로고
    • Influenza: Epidemiology, clinical features, therapy, and prevention
    • Clark NM, Lynch JP 3rd. Influenza: epidemiology, clinical features, therapy, and prevention. Semin Respir Crit Care Med 2011;32:373-92.
    • (2011) Semin Respir Crit Care Med , vol.32 , pp. 373-392
    • Clark, N.M.1    Lynch III, J.P.2
  • 5
    • 10944240992 scopus 로고    scopus 로고
    • Influenza: Old and new threats
    • Palese P. Influenza: old and new threats. Nat Med 2004;10: S82-7.
    • (2004) Nat Med , vol.10
    • Palese, P.1
  • 6
    • 0035969773 scopus 로고    scopus 로고
    • Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus
    • Taubenberger JK, Reid AH, Janczewski TA, Fanning TG. Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus. Philos Trans R Soc Lond B Biol Sci 2001; 356:1829-39.
    • (2001) Philos Trans R Soc Lond B Biol Sci , vol.356 , pp. 1829-1839
    • Taubenberger, J.K.1    Reid, A.H.2    Janczewski, T.A.3    Fanning, T.G.4
  • 7
    • 67650407532 scopus 로고    scopus 로고
    • Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans
    • Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 2009;325:197-201.
    • (2009) Science , vol.325 , pp. 197-201
    • Garten, R.J.1    Davis, C.T.2    Russell, C.A.3    Shu, B.4    Lindstrom, S.5    Balish, A.6
  • 8
    • 67749131251 scopus 로고    scopus 로고
    • Transmission and pathogenesis of swine-origin 2009 A (H1N1) influenza viruses in ferrets and mice
    • Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, et al. Transmission and pathogenesis of swine-origin 2009 A (H1N1) influenza viruses in ferrets and mice. Science 2009;325:484-7.
    • (2009) Science , vol.325 , pp. 484-487
    • Maines, T.R.1    Jayaraman, A.2    Belser, J.A.3    Wadford, D.A.4    Pappas, C.5    Zeng, H.6
  • 9
    • 84865307690 scopus 로고    scopus 로고
    • Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study
    • Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012;12: 687-95.
    • (2012) Lancet Infect Dis , vol.12 , pp. 687-695
    • Dawood, F.S.1    Iuliano, A.D.2    Reed, C.3    Meltzer, M.I.4    Shay, D.K.5    Cheng, P.Y.6
  • 10
    • 84862610867 scopus 로고    scopus 로고
    • The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host
    • Russell CA, Fonville JM, Brown AE, Burke DF, Smith DL, James SL, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science 2012;336:1541-7.
    • (2012) Science , vol.336 , pp. 1541-1547
    • Russell, C.A.1    Fonville, J.M.2    Brown, A.E.3    Burke, D.F.4    Smith, D.L.5    James, S.L.6
  • 12
    • 80052729507 scopus 로고    scopus 로고
    • Swine-origin influenza A (H3N2) virus infection in two cildren--Indiana and Pennsylvania
    • CDC, July-August 2011
    • CDC. Swine-origin influenza A (H3N2) virus infection in two cildren--Indiana and Pennsylvania, July-August 2011. MMWR Morb Mortal Wkly Rep 2011;60:1213-5.
    • (2011) MMWR Morb Mortal Wkly Rep , vol.60 , pp. 1213-1215
  • 13
    • 84866415882 scopus 로고    scopus 로고
    • Notes from the field: Highly pathogenic avian influenza A (H7N3) virus infection in two poultry workers - Jalisco
    • CDC, Mexico, July 2012
    • CDC. Notes from the field: Highly pathogenic avian influenza A (H7N3) virus infection in two poultry workers - Jalisco, Mexico, July 2012. MMWR Morb Mortal Wkly Rep 2012; 61:726-7.
    • (2012) MMWR Morb Mortal Wkly Rep , vol.61 , pp. 726-727
  • 14
    • 0034072605 scopus 로고    scopus 로고
    • Mismatch between the 1997/1998 influenza vaccine and the major epidemic A (H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly
    • de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A (H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000;61:94-9.
    • (2000) J Med Virol , vol.61 , pp. 94-99
    • de Jong, J.C.1    Beyer, W.E.2    Palache, A.M.3    Rimmelzwaan, G.F.4    Osterhaus, A.D.5
  • 15
    • 33947131140 scopus 로고    scopus 로고
    • Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005-2006 season of dual A and B vaccine mismatch in Canada
    • Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007;25:2842-51.
    • (2007) Vaccine , vol.25 , pp. 2842-2851
    • Skowronski, D.M.1    Masaro, C.2    Kwindt, T.L.3    Mak, A.4    Petric, M.5    Li, Y.6
  • 16
    • 47549100591 scopus 로고    scopus 로고
    • Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children
    • Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008;47:339-45.
    • (2008) Clin Infect Dis , vol.47 , pp. 339-345
    • Sugaya, N.1    Tamura, D.2    Yamazaki, M.3    Ichikawa, M.4    Kawakami, C.5    Kawaoka, Y.6
  • 17
    • 84865705973 scopus 로고    scopus 로고
    • Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households
    • Carrat F, Duval X, Tubach F, Mosnier A, Van der Werf S, Tibi A, et al. Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. Antivir Ther 2012;17:1085-90.
    • (2012) Antivir Ther , vol.17 , pp. 1085-1090
    • Carrat, F.1    Duval, X.2    Tubach, F.3    Mosnier, A.4    Van der Werf, S.5    Tibi, A.6
  • 18
    • 77950202365 scopus 로고    scopus 로고
    • H1N1 novel influenza A in pregnant and immunocompromised patients
    • Lapinsky SE. H1N1 novel influenza A in pregnant and immunocompromised patients. Crit Care Med 2010;38:e52-7.
    • (2010) Crit Care Med , vol.38
    • Lapinsky, S.E.1
  • 19
    • 78751614259 scopus 로고    scopus 로고
    • Oseltamivir, zanamivir and amantadine in the prevention of influenza: A systematic review
    • Jackson RJ, Cooper KL, Tappenden P, Rees A, Simpson EL, Read RC, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect 2011;62: 14-25.
    • (2011) J Infect , vol.62 , pp. 14-25
    • Jackson, R.J.1    Cooper, K.L.2    Tappenden, P.3    Rees, A.4    Simpson, E.L.5    Read, R.C.6
  • 20
    • 25444501243 scopus 로고    scopus 로고
    • Neuraminidase inhibitors for influenza
    • Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73.
    • (2005) N Engl J Med , vol.353 , pp. 1363-1373
    • Moscona, A.1
  • 21
    • 0033385681 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802
    • He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999;37:471-84.
    • (1999) Clin Pharmacokinet , vol.37 , pp. 471-484
    • He, G.1    Massarella, J.2    Ward, P.3
  • 22
    • 77952576118 scopus 로고    scopus 로고
    • Pharmacokinetics of oseltamivir: An oral antiviral for the treatment and prophylaxis of influenza in diverse populations
    • Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010;65 Suppl 2:ii5-ii10.
    • (2010) J Antimicrob Chemother , vol.65 , Issue.2 SUPPL.
    • Davies, B.E.1
  • 23
    • 84860334106 scopus 로고    scopus 로고
    • Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods
    • Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 2012;17:159-73.
    • (2012) Antivir Ther , vol.17 , pp. 159-173
    • Nguyen, H.T.1    Fry, A.M.2    Gubareva, L.V.3
  • 24
    • 33745635392 scopus 로고    scopus 로고
    • Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use
    • Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-402.
    • Antimicrob Agents Chemother 2006; , vol.50 , pp. 2395-2402
    • Monto, A.S.1    McKimm-Breschkin, J.L.2    Macken, C.3    Hampson, A.W.4    Hay, A.5    Klimov, A.6
  • 28
    • 65549143369 scopus 로고    scopus 로고
    • Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A (H1N1) viruses
    • Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007--lack of association with the appearance of oseltamivir-resistant influenza A (H1N1) viruses. Euro Surveill 2009;14.
    • (2009) Euro Surveill , pp. 14
    • Kramarz, P.1    Monnet, D.2    Nicoll, A.3    Yilmaz, C.4    Ciancio, B.5
  • 29
    • 0036294323 scopus 로고    scopus 로고
    • The H274Y mutation in the influenza A/H1N1 neura-minidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo
    • Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, et al. The H274Y mutation in the influenza A/H1N1 neura-minidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002;55:307-17.
    • (2002) Antiviral Res , vol.55 , pp. 307-317
    • Ives, J.A.1    Carr, J.A.2    Mendel, D.B.3    Tai, C.Y.4    Lambkin, R.5    Kelly, L.6
  • 30
    • 77953262416 scopus 로고    scopus 로고
    • Permissive secondary mutations enable the evolution of influenza oseltamivir resistance
    • Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010;328:1272-5.
    • (2010) Science , vol.328 , pp. 1272-1275
    • Bloom, J.D.1    Gong, L.I.2    Baltimore, D.3
  • 31
    • 33845455661 scopus 로고    scopus 로고
    • Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child
    • Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43:1555-61.
    • (2006) Clin Infect Dis , vol.43 , pp. 1555-1561
    • Baz, M.1    Abed, Y.2    McDonald, J.3    Boivin, G.4
  • 32
    • 79851471047 scopus 로고    scopus 로고
    • Generation and characterization of recombinant pandemic influenza A (H1N1) viruses resistant to neuraminidase inhibitors
    • Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A (H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011;203:25-31.
    • (2011) J Infect Dis , vol.203 , pp. 25-31
    • Pizzorno, A.1    Bouhy, X.2    Abed, Y.3    Boivin, G.4
  • 33
    • 79955402165 scopus 로고    scopus 로고
    • Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus
    • Kiso M, Ozawa M, Le MT, Imai H, Takahashi K, Kakugawa S, et al. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus. J Virol 2011;85:4667-72.
    • (2011) J Virol , vol.85 , pp. 4667-4672
    • Kiso, M.1    Ozawa, M.2    Le, M.T.3    Imai, H.4    Takahashi, K.5    Kakugawa, S.6
  • 34
    • 0034099655 scopus 로고    scopus 로고
    • Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus
    • Mitnaul LJ, Matrosovich MN, Castrucci MR, Tuzikov AB, Bovin NV, Kobasa D, et al. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J Virol 2000;74:6015-20.
    • (2000) J Virol , vol.74 , pp. 6015-6020
    • Mitnaul, L.J.1    Matrosovich, M.N.2    Castrucci, M.R.3    Tuzikov, A.B.4    Bovin, N.V.5    Kobasa, D.6
  • 35
    • 84855949218 scopus 로고    scopus 로고
    • Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses
    • Ginting TE, Shinya K, Kyan Y, Makino A, Matsumoto N, Kaneda S, et al. Amino acid changes in hemagglutinin contribute to the replication of oseltamivir-resistant H1N1 influenza viruses. J Virol 2012;86:121-7.
    • (2012) J Virol , vol.86 , pp. 121-127
    • Ginting, T.E.1    Shinya, K.2    Kyan, Y.3    Makino, A.4    Matsumoto, N.5    Kaneda, S.6
  • 36
    • 84864117825 scopus 로고    scopus 로고
    • Enhanced mammalian trans-missibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase
    • Bouvier NM, Rahmat S, Pica N. Enhanced mammalian trans-missibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase. J Virol 2012;86:7268-79.
    • (2012) J Virol , vol.86 , pp. 7268-7279
    • Bouvier, N.M.1    Rahmat, S.2    Pica, N.3
  • 38
    • 38449093101 scopus 로고    scopus 로고
    • DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection
    • Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, Lee A, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007;196:1493-9.
    • (2007) J Infect Dis , vol.196 , pp. 1493-1499
    • Belser, J.A.1    Lu, X.2    Szretter, K.J.3    Jin, X.4    Aschenbrenner, L.M.5    Lee, A.6
  • 40
    • 77749306182 scopus 로고    scopus 로고
    • Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection
    • Hedlund M, Aschenbrenner LM, Jensen K, Larson JL, Fang F. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J Infect Dis 2010;201: 1007-15.
    • (2010) J Infect Dis , vol.201 , pp. 1007-1015
    • Hedlund, M.1    Aschenbrenner, L.M.2    Jensen, K.3    Larson, J.L.4    Fang, F.5
  • 41
    • 0344938363 scopus 로고    scopus 로고
    • Antiviral drugs
    • Balfour HH Jr. Antiviral drugs. N Engl J Med 1999;340:1255-68.
    • (1999) N Engl J Med , vol.340 , pp. 1255-1268
    • Balfour, H.H.1
  • 42
    • 1942468738 scopus 로고    scopus 로고
    • Antiviral chemo-therapeutic agents against respiratory viruses: Where are we now and what's in the pipeline?
    • Brooks MJ, Sasadeusz JJ, Tannock GA. Antiviral chemo-therapeutic agents against respiratory viruses: where are we now and what's in the pipeline? Curr Opin Pulm Med 2004; 10:197-203.
    • (2004) Curr Opin Pulm Med , vol.10 , pp. 197-203
    • Brooks, M.J.1    Sasadeusz, J.J.2    Tannock, G.A.3
  • 43
    • 64749093901 scopus 로고    scopus 로고
    • T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
    • Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009;82:95-102.
    • (2009) Antiviral Res , vol.82 , pp. 95-102
    • Furuta, Y.1    Takahashi, K.2    Shiraki, K.3    Sakamoto, K.4    Smee, D.F.5    Barnard, D.L.6
  • 44
    • 80054709041 scopus 로고    scopus 로고
    • Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection
    • Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011;55:5267-76.
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 5267-5276
    • Kohno, S.1    Yen, M.Y.2    Cheong, H.J.3    Hirotsu, N.4    Ishida, T.5    Kadota, J.6
  • 45
    • 79956299861 scopus 로고    scopus 로고
    • Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients
    • Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011;55:2803-12.
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 2803-2812
    • Kohno, S.1    Kida, H.2    Mizuguchi, M.3    Hirotsu, N.4    Ishida, T.5    Kadota, J.6
  • 46
    • 73349121665 scopus 로고    scopus 로고
    • The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza
    • Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009;361:2204-7.
    • (2009) N Engl J Med , vol.361 , pp. 2204-2207
    • Birnkrant, D.1    Cox, E.2
  • 47
    • 80053629582 scopus 로고    scopus 로고
    • Laninamivir octanoate: A new long-acting neuraminidase inhibitor for the treatment of influenza
    • Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther 2011;9:851-7.
    • (2011) Expert Rev Anti Infect Ther , vol.9 , pp. 851-857
    • Ikematsu, H.1    Kawai, N.2
  • 48
    • 0032515589 scopus 로고    scopus 로고
    • Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus
    • Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-71.
    • (1998) Lancet , vol.351 , pp. 467-471
    • Yuen, K.Y.1    Chan, P.K.2    Peiris, M.3    Tsang, D.N.4    Que, T.L.5    Shortridge, K.F.6
  • 49
    • 33749511112 scopus 로고    scopus 로고
    • Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia
    • de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006;12:1203-7.
    • (2006) Nat Med , vol.12 , pp. 1203-1207
    • de Jong, M.D.1    Simmons, C.P.2    Thanh, T.T.3    Hien, V.M.4    Smith, G.J.5    Chau, T.N.6
  • 50
    • 34547619982 scopus 로고    scopus 로고
    • Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection
    • Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A 2007;104: 12479-81.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 12479-12481
    • Salomon, R.1    Hoffmann, E.2    Webster, R.G.3
  • 54
    • 0036244498 scopus 로고    scopus 로고
    • Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin
    • Smee DF, Bailey KW, Morrison AC, Sidwell RW. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002;48:88-93.
    • (2002) Chemotherapy , vol.48 , pp. 88-93
    • Smee, D.F.1    Bailey, K.W.2    Morrison, A.C.3    Sidwell, R.W.4
  • 56
    • 77956937502 scopus 로고    scopus 로고
    • Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice
    • Smee DF, Hurst BL, Wong MH, Tarbet EB, Babu YS, Klumpp K, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res 2010;88:38-44.
    • (2010) Antiviral Res , vol.88 , pp. 38-44
    • Smee, D.F.1    Hurst, B.L.2    Wong, M.H.3    Tarbet, E.B.4    Babu, Y.S.5    Klumpp, K.6
  • 57
    • 34447513687 scopus 로고    scopus 로고
    • Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice
    • Masihi KN, Schweiger B, Finsterbusch T, Hengel H. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice. J Chemother 2007;19:295-303.
    • (2007) J Chemother , vol.19 , pp. 295-303
    • Masihi, K.N.1    Schweiger, B.2    Finsterbusch, T.3    Hengel, H.4
  • 58
    • 84859053626 scopus 로고    scopus 로고
    • Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice
    • Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res 2012;94:103-10.
    • (2012) Antiviral Res , vol.94 , pp. 103-110
    • Tarbet, E.B.1    Maekawa, M.2    Furuta, Y.3    Babu, Y.S.4    Morrey, J.D.5    Smee, D.F.6
  • 59
    • 33845462128 scopus 로고    scopus 로고
    • Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice
    • Galabov AS, Simeonova L, Gegova G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir Chem Chemother 2006;17:251-8.
    • (2006) Antivir Chem Chemother , vol.17 , pp. 251-258
    • Galabov, A.S.1    Simeonova, L.2    Gegova, G.3
  • 60
    • 78650232558 scopus 로고    scopus 로고
    • Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model
    • Bantia S, Kellogg D, Parker CD, Babu YS. Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antiviral Res 2010;88:276-80.
    • (2010) Antiviral Res , vol.88 , pp. 276-280
    • Bantia, S.1    Kellogg, D.2    Parker, C.D.3    Babu, Y.S.4
  • 61
    • 70349443188 scopus 로고    scopus 로고
    • Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells
    • Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother 2009;64:741-6.
    • (2009) J Antimicrob Chemother , vol.64 , pp. 741-746
    • Smee, D.F.1    Hurst, B.L.2    Egawa, H.3    Takahashi, K.4    Kadota, T.5    Furuta, Y.6
  • 62
  • 64
    • 33947105014 scopus 로고    scopus 로고
    • Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses
    • Smee DF, Wong MH, Bailey KW, Sidwell RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 2006;17:185-92.
    • (2006) Antivir Chem Chemother , vol.17 , pp. 185-192
    • Smee, D.F.1    Wong, M.H.2    Bailey, K.W.3    Sidwell, R.W.4
  • 65
    • 79952161350 scopus 로고    scopus 로고
    • Mixing the right hepatitis C inhibitor cocktail
    • Gelman MA, Glenn JS. Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med 2010.
    • (2010) Trends Mol Med
    • Gelman, M.A.1    Glenn, J.S.2
  • 66
    • 84860908013 scopus 로고    scopus 로고
    • Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection
    • Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, et al. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 2012;8:e1002506.
    • (2012) PLoS Pathog , vol.8
    • Evering, T.H.1    Mehandru, S.2    Racz, P.3    Tenner-Racz, K.4    Poles, M.A.5    Figueroa, A.6
  • 67
    • 40849130832 scopus 로고    scopus 로고
    • Current and future antiviral therapy of severe seasonal and avian influenza
    • Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008;78:91-102.
    • (2008) Antiviral Res , vol.78 , pp. 91-102
    • Beigel, J.1    Bray, M.2
  • 68
    • 70349331605 scopus 로고    scopus 로고
    • Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro
    • Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, Engelthaler DM, et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009;53:4115-26.
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 4115-4126
    • Nguyen, J.T.1    Hoopes, J.D.2    Smee, D.F.3    Prichard, M.N.4    Driebe, E.M.5    Engelthaler, D.M.6
  • 69
    • 79959238506 scopus 로고    scopus 로고
    • Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator-and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v
    • Petersen E, Keld DB, Ellermann-Eriksen S, Gubbels S, Ilkjaer S, Jensen-Fangel S, et al. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator-and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis 2011;43: 495-503.
    • (2011) Scand J Infect Dis , vol.43 , pp. 495-503
    • Petersen, E.1    Keld, D.B.2    Ellermann-Eriksen, S.3    Gubbels, S.4    Ilkjaer, S.5    Jensen-Fangel, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.